Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation

Table 1: Results of multicentre trials of tracrolimus and cyclosporine for immunosuppression after liver transplantation
Study and group No. of patients Rate of acute rejection, % of patients Rate of refractory rejection, % of patients

United States Multicenter Liver Study Group²
Tacrolimus
Cyclosporine 263
266 68*
76* 3*
15*

European Multicenter Liver Study Group²
Tacrolimus
Cyclosporine 267
273 42*
55* 3*
10*

*Significant difference (p < 0.01).

[Return to text]

Table 1: Results of multicentre trials of tracrolimus and cyclosporine for immunosuppression after liver transplantation
Study and group	No. of patients	Rate of acute rejection, % of patients	Rate of refractory rejection, % of patients
United States Multicenter Liver Study Group² Tacrolimus Cyclosporine	263 266	68* 76*	3* 15*
European Multicenter Liver Study Group² Tacrolimus Cyclosporine	267 273	42* 55*	3* 10*
*Significant difference (p < 0.01).